MedTrace Logo

The Clinical Trial of Cefuroxime Axetil Dispersible Tablets

NCT03020940 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100000

Last updated 2017-01-13

No results posted yet for this study

Summary

1. National, large-scale, standardized, standardized, real-world research;
2. Prospective, single - arm open, non - interventional, registration, multi - center clinical study;
3. in the use of cefuroxime axetil dispersible tablets in the hospital, according to the principle of voluntary selection of 200;
4. registration of the use of cefuroxime axetil dispersion tablets patients;
5. Target sample size of 100,000 cases;
6. Exemption from informed consent for ethical review applications;
7. Antibiotic drug safety re-evaluation of large data.

Conditions

Interventions

DRUG

Cefuroxime Axetil Dispersible Tablets

Oral. This product can be taken orally, can also be added to the amount of warm water after mixing evenly. Adult general 0.25g (one time), 2 times a day, the general course of treatment for 5 to 10 days. Severe Infection or suspected pneumonia, a 0.5g (once 2), 2 times a day; general urinary tract infection, a Times a 0.125g (one and a half tablets), 2 times a day; for patients with no complications of gonorrhea recommended dose of 1g (4 Tablets), a single taking. Children generally a dose of 0.125g (one-half tablets), 2 times a day; for less than two years of age in the middle ear Inflammatory patients, a 0.125g (one half tablets), 2 times a day; for greater than two years of otitis media patients, one Times a 0.25g (one time), 2 times a day; more than 12 years of age in children, the same dose for adults

Sponsors & Collaborators

  • Jiangsu Famous Medical Technology Co., Ltd.

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2019-11-30
Completion
2019-11-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03020940 on ClinicalTrials.gov